Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (HLN) covers the month of May 2026, specifically dated May 1, 2026. Haleon is a consumer health company focused on everyday health across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The filing primarily discloses capital structure and voting rights data as of April 30, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on share capital and voting rights.
- Total Ordinary Shares Issued: 8,891,932,595 (par value £0.01 each)
- Treasury Shares: 12,240,797
- Shares with Voting Rights: 8,879,691,798
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It serves as a statutory notification of the current share count for regulatory compliance under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
No financial guidance, outlook, management commentary on performance, or specific risk factors are included in this document. The text reiterates the company's mission to improve everyday health through its portfolio of trusted brands, including Advil, Centrum, Panadol, Sensodyne, and Voltaren.
Investor Verification Checklist
- Verify the denominator for notifiable interest calculations is 8,879,691,798 shares.
- Confirm the treasury share count of 12,240,797 remains accurate for current ownership analysis.
- Note that this filing contains no financial performance data; refer to Form 20-F or quarterly reports for revenue and earnings.
- Ensure any notifiable interests are reported to company.secretary@haleon.com.